TCL Archive Reaction To PSA Guideline Muffled Compared to 2009 Mammography Guideline October 14, 2011
TCL Archive NCI to Press FDA For Quicker Drug Approval, Relaxation Of Survival Impact Requirement June 26, 1987
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive ODAC Endorses Tamoxifen Trial, With Modification to Ensure Enrollment of Women At Higher Risk August 2, 1991
